The Pangenomic Classification of Pituitary Neuroendocrine Tumors: Quality Histopathology is Required for Accurate Translational Research

Ozgur Mete¹, Shereen Ezzat², Arie Perry³, Shozo Yamada^{4

5}, Silvia Uccella⁶, Ashley B Grossman^{7

8}, Sylvia L Asa⁹

Affiliations

¹ Department of Pathology, University Health Network and University of Toronto, Toronto, Canada. ozgur.mete2@uhn.ca.
² Department of Medicine, University Health Network and University of Toronto, Toronto, Canada.
³ Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.
⁴ Department of Neurosurgery, Toranomon Hospital, Tokyo Neurological Center, Tokyo, Japan.
⁵ Hypothalamic and Pituitary Center, Moriyama Memorial Hospital, Tokyo, Japan.
⁶ Department of Pathology, University of Insubria, Varese, Italy.
⁷ Centre for Endocrinology, Barts and the London School of Medicine, London, UK.
⁸ Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
⁹ Department of Pathology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA.

Comment

Ozgur Mete et al. Endocr Pathol. 2021 Sep.

. 2021 Sep;32(3):415-417.

doi: 10.1007/s12022-021-09671-4. Epub 2021 Mar 3.

Ozgur Mete¹, Shereen Ezzat², Arie Perry³, Shozo Yamada^{4

5}, Silvia Uccella⁶, Ashley B Grossman^{7

8}, Sylvia L Asa⁹

¹ Department of Pathology, University Health Network and University of Toronto, Toronto, Canada. ozgur.mete2@uhn.ca.
² Department of Medicine, University Health Network and University of Toronto, Toronto, Canada.
³ Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.
⁴ Department of Neurosurgery, Toranomon Hospital, Tokyo Neurological Center, Tokyo, Japan.
⁵ Hypothalamic and Pituitary Center, Moriyama Memorial Hospital, Tokyo, Japan.
⁶ Department of Pathology, University of Insubria, Varese, Italy.
⁷ Centre for Endocrinology, Barts and the London School of Medicine, London, UK.
⁸ Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
⁹ Department of Pathology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA.

No abstract available

Keywords: Pangenomic classification; Pituitary adenoma; Pituitary neuroendocrine tumor.

Comment on

Pangenomic Classification of Pituitary Neuroendocrine Tumors.
Neou M, Villa C, Armignacco R, Jouinot A, Raffin-Sanson ML, Septier A, Letourneur F, Diry S, Diedisheim M, Izac B, Gaspar C, Perlemoine K, Verjus V, Bernier M, Boulin A, Emile JF, Bertagna X, Jaffrezic F, Laloe D, Baussart B, Bertherat J, Gaillard S, Assié G. Neou M, et al. Cancer Cell. 2020 Jan 13;37(1):123-134.e5. doi: 10.1016/j.ccell.2019.11.002. Epub 2019 Dec 26. Cancer Cell. 2020. PMID: 31883967

1. Neou M, Villa C, Armignacco R et al. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell 2020; 37(1):123-134. - DOI
1. Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998; 19:798-827. - PubMed
1. Mete O, Cintosun A, Pressman I, Asa SL. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol 2018; 31(6):900-909. - DOI
1. Mete O, Asa SL. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocr Pathol 2020; 31(4):330-336. - DOI
1. Mete O, Kefeli M, Caliskan S, Asa SL. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Mod Pathol 2019; 32(4):484-489. - DOI